home / stock / bold / bold news

BOLD News and Press, Audentes Therapeutics Inc. From 01/31/19

Stock Information
Company Name: Audentes Therapeutics Inc.
Stock Symbol: BOLD
Market: NASDAQ
Website: boundlessbio.com
Menu
BOLD BOLD Quote BOLD Short BOLD News BOLD Articles BOLD Message Board
Get BOLD Alerts

News, Short Squeeze, Breakout and More Instantly...
BOLD - Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation

SAN FRANCISCO , Jan. 31, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today provided an update...
BOLD - Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities

SAN FRANCISCO , Jan. 7, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today provided an update ...

BOLD - Audentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO , Jan. 2, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Pat...

BOLD - Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO , Dec. 7, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted ...
BOLD - Audentes down 21% after Q3 report and pipeline update

Audentes Therapeutics ( BOLD -21.3% ) slumps on a 4x surge in volume after its Q3 report and business update released after the close yesterday. Key events/milestones: More news on: Audentes Therapeutics, Read more ...

BOLD - Audentes Therapeutics (BOLD) CEO Matt Patterson on Q3 2018 Results - Earnings Call Transcript

Audentes Therapeutics (BOLD) Q3 2018 Earnings Conference Call November 6, 2018 04:30 PM ET Executives Matt Patterson - President and CEO Tom Soloway - SVP and CFO Natalie Holles - President and COO Suyash Prasad - SVP and CMO Andrew Chang - Director of IR Analysts Ritu ...

BOLD - Audentes Therapeutics misses by $0.09

Audentes Therapeutics (NASDAQ: BOLD ): Q3 GAAP EPS of -$0.97 misses by $0.09. More news on: Audentes Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...

BOLD - Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

SAN FRANCISCO , Nov. 6, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financ...

BOLD - Notable earnings after Tuesday's close

ACAD , AAXN , AIZ , APEI , ASH , BEL , BOLD , BWXT , CHUY , COHR , CPE , CSLT , CUTR , CWH , DAR , DATA , DIOD , DK , DOOR , DPLO , DVN , DXC , DXCM , EGN , ENLC , ENLK , ENPH , ETSY , EVH , EVRI , FANG , FIVN , FTK , FTR , G , GDDY , GHDX , GLUU , HAL...

BOLD - Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman

SAN FRANCISCO , Nov. 5, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Co-F...
Previous 10 Next 10